These compounds have been developed based on the hypothesis that selective activation of the G-protein signal pathway via MOP mediates the analgesic effect by avoiding stimulation of ß-arrestin signaling, which is believed to induce adverse opioid effects such as respiratory depression and constipation. This evidence concerns the gene SAG and Respiratory insufficiency due to muscle weakness.